Virtual Incision Earns Approval to Complete Clinical Study for Miniaturized Surgery Platform
Virtual Incision Corporation, which is developing a miniaturized robotic-assisted surgery (RAS) platform, has announced the Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) supplement. This will complete the final stage of its clinical study analyzing the MIRA Platform in bowel resection procedures. Virtual Incision said the approval was supported by a favorable interim clinical study report on the safety profile of MIRA.